<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030849</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069202</org_study_id>
    <secondary_id>MSKCC-01128</secondary_id>
    <secondary_id>NCI-G01-2049</secondary_id>
    <nct_id>NCT00030849</nct_id>
  </id_info>
  <brief_title>Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.&#xD;
      Combining chemotherapy with interferon alfa may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon&#xD;
      alfa in treating patients who have cutaneous T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate and response duration in patients with cutaneous T-cell&#xD;
           lymphoma when treated with bexarotene and, in the absence of a complete response,&#xD;
           interferon alfa.&#xD;
&#xD;
        -  Determine the safety and toxicity in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral bexarotene once daily for 8 weeks.&#xD;
&#xD;
      Patients with a complete response (CR) after 8 weeks continue bexarotene alone for at least&#xD;
      another 8 weeks in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients who progress or relapse during bexarotene therapy or who achieve less than a CR&#xD;
      after 8 weeks begin receiving interferon alfa subcutaneously 3 times a week and oral&#xD;
      bexarotene daily for at least another 8 weeks in the absence of continuing disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-45 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous T-cell lymphoma&#xD;
&#xD;
               -  Stage IB, IIA, IIB, III, or IV&#xD;
&#xD;
          -  Measurable or assessable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  WBC at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 70,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
          -  Fasting triglyceride normal (normalization with an antilipemic agent is allowed prior&#xD;
             to study)&#xD;
&#xD;
          -  No severe decompensated liver disease (e.g., cirrhosis, autoimmune hepatitis, or any&#xD;
             other significant liver dysfunction)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Calcium no greater than 11.5 mg/dL&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction in the past 6 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No class III or IV congestive heart failure&#xD;
&#xD;
          -  No ventricular tachyarrhythmias&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary infiltrates or clinical pulmonary impairment&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception for 1 month before,&#xD;
             during, and for 1 month after study therapy&#xD;
&#xD;
          -  No known allergy or sensitivity to interferon alfa or bexarotene or other components&#xD;
             of study drugs&#xD;
&#xD;
          -  No uncontrolled thyroid disorder&#xD;
&#xD;
          -  No other concurrent serious medical illness that would preclude study&#xD;
&#xD;
          -  No infection&#xD;
&#xD;
          -  No history of pancreatitis&#xD;
&#xD;
          -  No history of neuropsychiatric disorders requiring hospitalization&#xD;
&#xD;
          -  No history of autoimmune disease that would pose significant risk&#xD;
&#xD;
          -  Must be willing and able to avoid prolonged exposure to the sun or ultraviolet light&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent systemic anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent localized radiotherapy to target lesions unless considered&#xD;
&#xD;
          -  to have shown progressive disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior systemic doses of more than 15,000 IU per day of vitamin&#xD;
             A or any other retinoid class drug&#xD;
&#xD;
          -  At least 30 days since prior participation in any other investigational drug study&#xD;
&#xD;
          -  No concurrent systemic anti-psoriatic drugs or therapies&#xD;
&#xD;
          -  No concurrent systemic other anticancer drugs or therapies&#xD;
&#xD;
          -  No concurrent gemfibrozil&#xD;
&#xD;
          -  No other concurrent investigational medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Straus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 1;109(9):1799-803.</citation>
    <PMID>17366595</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

